# Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

> **NCT01844076** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Quinacrine and Capecitabine

## Key facts

- **NCT ID:** NCT01844076
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-14
- **Primary completion:** 2019-08-09
- **Final completion:** 2019-08-09
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The single Quinacrine manufacture facility in the US was shut down by the FDA
- **Last updated:** 2021-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844076, "Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01844076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*